GO Therapeutics
GO Therapeutics is advancing ADCs by targeting novel glycoproteins found exclusively on cancer cells. Its proprietary platform identifies “super-clean” tumor-specific antigens, enabling highly selective antibody development. Based in Cambridge, GO’s ADCs deliver potent payloads with minimal off-target effects, improving safety and efficacy in solid tumors. The company’s pipeline includes next-generation ADCs designed to overcome limitations of conventional therapies. GO Therapeutics is redefining precision oncology by unlocking new antigen classes for smarter, cleaner cancer treatment.
